Pharmacology · Class

Thrombopoietin receptor agonists !

Drugs that switch on the thrombopoietin receptor so the marrow makes more platelets, used mainly in chronic immune thrombocytopenia.

Updated 2026-11-01

What they are

Romiplostim (a peptide on an antibody fragment, injected weekly) and eltrombopag (an oral small molecule) stimulate megakaryocytes. They are used when immune thrombocytopenia responds poorly to other treatments; eltrombopag is also used in severe aplastic anaemia and hepatitis C-related thrombocytopenia. The goal is a safe platelet count, not a normal one.

Mechanism of action

They activate MPL, the thrombopoietin receptor, on megakaryocyte progenitors, increasing megakaryocyte growth and platelet production. Romiplostim binds the extracellular part of the receptor; eltrombopag binds its transmembrane domain.

Target: Thrombopoietin receptor (MPL)

Drugs in this class

Others in the class

avatrombopag
lusutrombopag

Test yourself

Think of the answer, then tap the question to see it.

Which receptor do these drugs activate?

MPL, the thrombopoietin receptor.

Which one is oral?

Eltrombopag (romiplostim is a weekly subcutaneous injection).

Is the target a normal platelet count?

No; a count that lowers the bleeding risk.

Add to my cards (3)

← All of pharmacology

Educational content on how drugs work; not a prescribing guide and no substitute for a health professional's advice. No doses are given.

Sources: Farmacología básica y clínica (Katzung), 16.ª ed., cap. 33 (McGraw Hill, 2025); Goodman & Gilman's The Pharmacological Basis of Therapeutics, 14th ed., ch. 45 (McGraw Hill, 2023); Romiplostim Injection: MedlinePlus Drug Information (MedlinePlus (U.S. National Library of Medicine), 2025); Eltrombopag: MedlinePlus Drug Information (MedlinePlus (U.S. National Library of Medicine), 2026).

Spotted a mistake?We are always improving for the community. Tell us what is wrong and our team will review it.Report a mistake

Representative model, for educational purposes only.